- Oral presentation to outline the development and preclinical evaluation of KY1049, the first fully human Factor VIII-mimetic bispecific antibody
- First development candidate generated using the IntelliSelect® Bispecific platform expected to enter clinical studies in 2021/22
Cambridge, UK; October 3, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced that an abstract describing KY1049, the Company’s fully human Factor VIII (FVIII)-mimetic bispecific antibody, will be presented at the European Congress on Thrombosis and Haemostasis (ECTH) in Glasgow, UK October 3, 2019.
The oral presentation will outline the development and preclinical evaluation of KY1049. KY1049 brings activated Factor IX into contact with Factor X, which restores hemostasis in plasma samples from Hemophilia A patients. KY1049 exemplifies Kymab’s proprietary IntelliSelect® Bispecific platform that can generate diverse and extensive panels of fully human, naturally-paired common light-chain (CLC) bispecific antibodies. Developed using clinically-relevant hemostatic assays, KY1049 is the first CLC bispecific antibody originating from Kymab’s proprietary IntelliSelect Bispecific platform. KY1049 is in preclinical development and is expected to enter clinical trials in 2021/22.
"KY1049 is an incredible technical achievement that exemplifies the power of our IntelliSelect Bispecific platform," said Allan Bradley, Ph.D., FRS, Chief Scientific Officer of Kymab. "These exciting data demonstrate that KY1049 rescues clotting and thrombin generation in plasma samples from patients with severe Hemophilia whether or not they have developed inhibitors to Factor VIII."
The details of the presentation are as follows:
Title: A fully human bispecific antibody for the treatment of Hemophilia A
Presenter: John Blackwood, Senior Research Scientist, Kymab
Session Title: FS 2.2: Focus Symposium: Treatment of Hemophilia
Location: Hall Alsh
Abstract ID #: ECTH-448
Date and Time: Thursday October 3, 9:30 – 10:30 a.m. BST
Notes to Editors
Read the PDF version of the official release.
KY1049 is a fully human common light-chain bispecific antibody discovered using the IntelliSelect® Bispecific platform – part of Kymab’s IntelliSelect® Suite of technologies. One arm of KY1049 binds to activated coagulation Factor IX (Factor IXa) while the other arm binds Factor X. This coincident binding brings the two coagulation Factors into physical proximity, allowing the coagulation cascade to function in the absence of Factor VIII.
Hemophilia A is an X-linked recessive genetic disorder resulting in a deficiency of Factor VIII and whose symptoms include increased bleeding and reduced blood clotting. KY1049 has been tested in plasma samples from Hemophilia A patients and can reproducibly restore the function of the coagulation cascade as measured by clotting time (aPTT, or activated partial thromboplastin time) and thrombin generation.
The IntelliSelect® Transgenics platforms are designed to generate fully human monoclonal antibodies from several highly-engineered strains of mice that have the complete constellation of human antibody building blocks in their genome.
The IntelliSelect® Screening technology combines single cell sequencing, genomics and proprietary bioinformatic algorithms to prioritize and select antibodies generated by IntelliSelect® Transgenics platforms that have the most desirable drug-like properties.
For more information please see http://www.kymab.com. Darwin is a trademark, and IntelliSelect® and Kymab are registered trademarks, of Kymab Limited.
Kymab is a clinical-stage biopharmaceutical company developing a deep pipeline of novel antibody-based therapies in a broad range of indications. The Company generates its product candidates using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s platforms have been designed to maximize the diversity of human antibodies produced in response to immunization with antigens. Selecting from a broad diversity of fully human antibodies allows for the identification of antibodies with optimal drug-like properties.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Dan Budwick, 1AB
Consilium Strategic Communications
Mary-Jane Elliott / Sukaina Virji / Melissa Gardiner
Tel: +44 (0) 20 3709 5700
Brandon Lewis, +44 (0)1223 833301